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Introduction
Treatment of intra-abdominal infections is challenging due to
the polymicrobial nature of infection and accompanying
morbidity and mortality. Treatment regimens must provide
broad-spectrum coverage, including Gram-positive and Gram-
negative aerobic and anaerobic bacteria of gastrointestinal
origin.1 Extended-spectrum penicillins such as piperacillin are
active against many Enterobacteriaceae, anaerobic bacteria
and Gram-positive cocci.2 Piperacillin exerts bactericidal
activity by inhibiting the process of septum and cell wall syn-
Randomized Comparison of Piperacillin/Tazobactam
Versus Imipenem/Cilastatin in the Treatment of Patients
with Intra-abdominal Infection
thesis; however, it is susceptible to degradation by bacterial β-
lactamase enzymes.3,4 Tazobactam is a β-lactamase inhibitor
that irreversibly binds a wide range of β-lactamase enzymes
but has little intrinsic antibacterial activity. The combination
of piperacillin and tazobactam results in broad-spectrum ac-
tivity which includes organisms that produce β-lactamases.5
The combination of piperacillin and tazobactam is safe
and effective when used as monotherapy in the treatment of
intra-abdominal infections.4,6–8 Clinical studies indicate that
imipenem/cilastatin is also quite effective in the treatment of
intra-abdominal infections.9,10 Studies comparing piperacillin/
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tazobactam with other broad-spectrum antibiotics demon-
strate favourable clinical response rates and bacterial eradi-
cation rates in patients receiving piperacillin/tazobac-
tam.3,4,8,11,12 In a clinical trial comparing piperacillin/tazo-
bactam with imipenem/cilastatin in the treatment of intra-
abdominal infections, the clinical cure rate was 91% with pip-
eracillin/tazobactam and 69% with imipenem/cilastatin (p =
0.005).11 Among microbiologically evaluable patients, the
infecting organisms were eradicated in 93% of piperacillin/
tazobactam-treated patients compared to 76% of imipenem/
cilastatin-treated patients (p = 0.029). Other clinical trials
demonstrate that piperacillin/tazobactam is equivalent in
safety and efficacy to imipenem/cilastatin in the treatment of
intra-abdominal infections.3,11
Studies have suggested that piperacillin/tazobactam
monotherapy may reduce overall treatment costs of moderate
to severe bacterial intra-abdominal infections when compared
to other commonly used antibiotic regimens, through fewer
relapses and lower daily therapeutic costs.13–15
The present study was conducted to evaluate the efficacy
and safety of piperacillin/tazobactam versus imipenem/
cilastatin in the treatment of intra-abdominal infections in an
Asian population.
Patients and methods
A regional, phase IV, multicentre, open-label, randomized
clinical trial was undertaken to compare the efficacy and safety
of two antimicrobials, piperacillin/tazobactam (4 g/500 mg
every 8 hours) and imipenem/cilastatin (500 mg/500 mg every
6 hours) in the treatment of intra-abdominal infections. Six
Asian countries/territories (China, Hong Kong, Malaysia, Ko-
rea, Philippines, and Thailand) participated. The study was
conducted in accordance with the Declaration of Helsinki,
and the Institutional Ethics Committees of the participating
centres approved the study protocol. Informed consent was
obtained before enrollment of each subject into the study.
Treatment duration was left to the discretion of the investigator.
The enrollment period was from July 1998 to May 2000. The
hypothesis tested was that the two treatment regimens,
piperacillin/tazobactam and imipenem/cilastatin, would be
equivalent in safety and efficacy.
Study participants
Hospitalized male or female patients over 18 years of age with
a confirmed diagnosis of intra-abdominal infection were eli-
gible for entry into the study. Evidence of peritonitis, intra-
abdominal abscess, appendicitis, cholecystitis or cholangitis
must have been present for enrollment. In addition, patients
were required to be candidates for laparotomy, laparoscopy or
percutaneous drainage of intra-abdominal abscess to treat
infection within 48 hours of signing the informed consent.
Patients were excluded from the trial if there was a history of
hypersensitivity to the study medications, infection with or-
ganisms known or suspected to be resistant to the study
medications, administration of other oral or parenteral anti-
bacterial agents, or peritoneal lavage with an antibacterial or
antiseptic agent within 48 hours prior to enrollment, more
than three doses of perioperative antibacterial prophylaxis if
enrolled postoperatively, presence of septic shock, granulo-
cytopenia (< 1,000/mm3), thrombocytopenia (< 50,000/mm3),
and creatinine clearance of 20 mL/minute or less requir-
ing dialysis. Patients with immune deficiency were also ex-
cluded.
Pre-therapy or baseline evaluations were performed after
patients signed the informed consent. These evaluations in-
cluded medical and medication history, a physical examina-
tion, the investigator’s assessment of the severity of the intra-
abdominal infection, and an assessment of the signs and
symptoms of intra-abdominal infection. Blood cultures and
infection site cultures for both aerobic and anaerobic bacte-
ria were also obtained at baseline.
Randomization and antibiotic therapy
In each centre, patients were centrally randomized in a 1:1
ratio to receive piperacillin/tazobactam or imipenem/cilastatin.
Patients randomized to the piperacillin/tazobactam group
received 4 g of piperacillin and 500 mg of tazobactam every 8
hours by slow intravenous infusion over 30 minutes. Patients
in the imipenem/cilastatin group received 500 mg each of
imipenem and cilastatin every 6 hours by slow intravenous
infusion over 30 minutes. Piperacillin/tazobactam, with its
three times daily dosing, offered an added advantage in this
study when compared to the four times daily dosing of
imipenem/cilastatin. In patients who presented with or who
developed some degree of impaired renal function not requir-
ing dialysis, the dosage of piperacillin/tazobactam was ad-
justed to 4 g/500 mg every 12 hours, and imipenem/cilastatin
dosage was adjusted to 250 mg/25 mg every 12 hours. No other
concomitant antibiotics were to be administered during the
study period.
Evaluations
Evaluations included clinical, bacteriological and laboratory
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parameters before initiation of therapy, at specified intervals
during treatment, at the end of therapy, and during early (9 ±
5 days post-therapy) and late follow-up (28 ± 7 days post-
therapy) periods.
All patients were monitored daily by the local investigator
for adverse events and clinical signs and symptoms of infection.
Bacteriological response was based on infection-site and blood
cultures taken at baseline through to the late follow-up period.
It was assessed at the patient level and pathogen level on the
last day of therapy and at follow-up visits. Laboratory param-
eters included blood chemistry and haematology on Days 3, 4
or 5 and every 3 to 5 days thereafter during treatment, on the
last day of therapy, and at early and late follow-up assessments.
Safety evaluations were based on data from physical
examination, vital signs, laboratory values (serum chemistry,
haematology and urinalysis), and adverse events.
Clinical and bacteriological definitions
The primary efficacy variable for this study was the clinical
success rate at the endpoint assessment (follow-up visit). Clini-
cal success was defined as a clinical response of either cured or
improved. A patient was considered cured if a full course of
therapy was completed, no further antimicrobial therapy was
required, and they had completely recovered from acute
infection. Patients were considered improved if there was a
favourable response at the end-of-therapy or post-therapy
evaluation, but without complete resolution.
Treatment was considered a failure if there was a lack of
response (i.e. if the patient’s signs and symptoms did not
improve or worsened, or if initial recovery was followed by
deterioration at early or late follow-up, or death due to intra-
abdominal infection) or the patient required antibacterial
therapy other than or in addition to the study drugs. Evalua-
tion was considered indeterminate if there was a change of
antibacterial therapy for reasons other than failure (e.g. devel-
opment of infections at a distant site), if the subject died of
non-infection related causes, or if the subject received less than
48 hours of treatment.
Secondary efficacy variables were bacteriological success
at both the patient and pathogen level. Bacteriological success
at both levels was defined as a response of eradication docu-
mented or presumed for each pathogen identified at baseline.
An infection was considered eradicated if the baseline patho-
gen was no longer present in a culture taken at the time of
clinical assessment (last day of therapy or follow-up visits). In
addition to assessing bacteriological response, each patient
was assessed for superinfections at the infection site. In pa-
tients with evidence of a new pathogen at the site of infection
at the follow-up visit, a clinical response of failure was docu-
mented as superinfection.
Statistical analysis
The sample size was determined based on the assumption that
the two treatments are equally effective. With favourable clini-
cal response rates (i.e. cure and improved) of 75% at the late
follow-up visit, 75 evaluable patients per treatment group were
required to ensure with 80% probability (i.e. 80% power) that
the upper and lower bound of a 95% confidence limit (95% CI)
for the true difference in efficacy do not exceed 20% (method of
Makuch and Simon with correction for continuity).16
For the purpose of analysis, four patient populations were
defined: intent-to-treat (ITT), clinically evaluable (CE), all
treated with a baseline pathogen (ATBP) and bacteriologically
evaluable (BE). The ITT population consisted of all patients
who received at least one dose of study medication. To be in-
cluded in the CE population, patients had a clinical response
other than indeterminate and met the following criteria: pres-
ence of intra-abdominal infection as defined by the protocol,
liver function tests less than five times the normal upper limit,
received 80% of prescribed dose of study drug between baseline
and last day of therapy, a minimum of 3 days of study drug,
modified doses of study drug if renally impaired, and had
a follow-up visit (early or late) unless the outcome was failure.
The BE population included all CE patients who also had a
pathogen isolated from an intra-abdominal source at the
baseline visit.
All statistical tests were two-tailed, and a p value of 0.05 or
less indicated statistical significance. The two-tailed 95% CIs
were constructed to detect differences in clinical and bacterio-
logical response rates between the treatment groups. Categori-
cal variables were compared between the treatments using
Fisher’s exact test.
Results
Altogether, 293 patients from 10 centres in six Asian coun-
tries/territories were included in the ITT population. There
were 134 patients from the Philippines, 74 from China, 50
from Korea, 20 from Hong Kong, eight from Thailand and
seven from Malaysia. There were 214 patients in the CE
population. Of these, 111 received piperacillin/tazobactam
and 103 received imipenem/cilastatin. Eight (7.2%) CE pa-
tients in the piperacillin/tazobactam group and seven (6.8%)
in the imipenem/cilastatin group discontinued the study
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early. The main reason for early discontinuation was loss to
follow-up.
The two treatment groups were very similar in all demo-
graphic and baseline characteristics for both the ITT and CE
populations. Among the CE population, patients were pre-
dominantly male (65%) and Oriental (99%). The age of CE
patients treated with piperacillin/tazobactam ranged from
17.0 to 95.0 years (mean, 42.9 years), and the age of those
treated with imipenem/cilastatin ranged from 17.0 to 90.0
years (mean, 41.3 years). Appendicitis was the most com-
mon primary diagnosis in both patient groups (49.5% in the
piperacillin/tazobactam group and 48.5% in the imipenem/
cilastatin group) (Table 1). Mean treatment duration was
5.6 ± 2.0 days (range, 3.0–15.0 days) in the piperacillin/
tazobactam group and 5.5 ± 2.1 days (range, 3.0–15.0 days)
in the imipenem/cilastatin group.
The primary efficacy endpoint was clinical success in
the CE population at the last patient evaluation for both
groups (Table 2). In both groups, 97% of patients (108/111 in
the piperacillin/tazobactam group and 100/103 in the
imipenem/cilastatin group) were either cured or improved
(p = 1.000).
The BE population included 133 patients, 69 in the
piperacillin/tazobactam group and 64 in the imipenem/
cilastatin group (Table 2). Among these, 67 patients (97%) in
the piperacillin/tazobactam group and 61 (95%) in the
imipenem/cilastatin group had bacterial eradication that was
either documented or presumed (p = 0.671). In the ATBP
population, 74 patients (85%) in the piperacillin/tazobactam
group and 76 patients (92%) in the imipenem/cilastatin group
had bacterial eradication that was either documented or pre-
sumed (95% CI, –16.1, 3.1; p = 0.236).
Table 1. Demographic characteristics of clinically evaluable patients
Piperacillin/tazobactam Imipenem/cilastatin Total
n (%) n (%) n (%)
Clinically evaluable 111/149 (74.5)1111111 103/144 (71.5)111111 214/293 (73.0)11111
Gender
   Male 74 (66.7)11 65 (63.1) 1 1 139 (65.0)111
   Female 37 (33.3)11 38 (36.9) 1 1 75 (35.0)11
Race
   Oriental 110 (99.1)111 101 (98.1) 11 211 (98.6)1
   Caucasian 0 (( 99)1 1 (0.97) 11 (0.47)
Age (yr)
   Mean ± SD 42.9 ± 18.3 1(1 41.3 ± 17.4 ((1 42.1 ± 17.9  (
   Range 17.0–95.0  ((1 17.0–90.01(1 17.0–95.0 1
Weight (kg)
   Mean ± SD 59.6 ± 8.6 11(1 61.1 ± 11.1 ((1 60.4 ± 9.9  (1
   Range 38.0–82.01 (1 39.6–95.01(1 38.0–95.0 1
Diagnosis
   Appendicitis 55 (49.5) 1 50 (48.5)1 105 (49.1)1
   Peritonitis* 25 (22.5) 1 29 (28.2)1 54 (25.2)
   Cholecystitis 15 (13.5) 1 11 (10.7)1 26 (12.1)
   Cholangitis 11 (9.9)1 1 8 (7.8)1 19 (8.9)1
   Intra-abdominal abscess 5 (4.5) 1 4 (3.9)1 9 (4.2)
   Other 0(99 1)1 1 (0.97) 11 (0.47)
Severity of infection†
   Moderate 73 (65.8) 1 67 (65.0)1 140 (65.4)1
   Severe 38 (34.2) 1 36 (35.0)1 74 (34.6)
*Spontaneous, postoperative, post-traumatic or secondary to perforated viscus; †based on clinical judgment of main investigator per site.
SD = standard deviation.
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Table 2. Clinical and bacteriological response rates
Outcome Piperacillin/tazobactam Imipenem/cilastatin p*
Clinically and bacteriologically evaluable patients
   Clinical response rate n = 111 n = 103
      Cured/improved 108 (97.3%)1 100 (97.1%)1 1.000
      Failure 3 (2.7%) 3 (2.9%)
   Patient-level bacteriological response rate† n = 69 n = 64
      Eradication documented/presumed 67 (97.1%) 61 (95.3%) 0.671
      Persistence documented/presumed 2 (2.9%) 3 (4.7%)
Intent-to-treat patients
   Clinical response rate n = 149 n = 144
      Cured/improved 124 (83.2%)1 126 (87.5%)1 0.232
      Failure/indeterminate 25 (16.8%) 18 (12.5%)
   Patient-level bacteriological response rate† n = 87 n = 83
      Eradication documented/presumed 74 (85.1%) 76 (91.6%) 0.236
      Persistence documented/presumed 6 (6.9%) 3 (3.6%)
      Indeterminate 7 (8.0%) 4 (4.8%)
      Superinfection 0 0
*Fisher’s exact test; †all treated patients with a baseline pathogen.
A total of 96 pathogens in the piperacillin/tazobactam
group and 99 in the imipenem/cilastatin group were isolated
at baseline. At the endpoint, the eradication rate of pathogens
in the piperacillin/tazobactam group was 94/96 (98%), and in
the imipenem/cilastatin group was 94/99 (95%). The most
common pathogens isolated were Escherichia coli, Klebsiella
species, Enterobacter species and Pseudomonas aeruginosa. At the
endpoint, eradication rates in the BE population were as fol-
lows: E. coli, 98% in the piperacillin/tazobactam group and 95%
in the imipenem/cilastatin group; Klebsiella species, 94% in the
piperacillin/tazobactam group and 93% in the imipenem/
cilastatin group; Enterobacter species, 100% in the piperacillin/
tazobactam group and 100% in the imipenem/cilastatin group;
and Pseudomonas aeruginosa, 100% in the piperacillin/tazo-
bactam group and 100% in the imipenem/cilastatin group
(Table 3). In the BE population, one patient in the piperacillin/
tazobactam group had Klebsiella pneumoniae as a superinfecting
pathogen.
Thirteen CE patients in the piperacillin/tazobactam group
and 18 in the imipenem/cilastatin group were bacteraemic
at baseline (Table 4). E. coli, K. pneumoniae and P. aeruginosa
were the most common pathogens among the bacteraemic
population. All patients in the piperacillin/tazobactam group
and 94% of patients in the imipenem/cilastatin group had
a patient-level bacteriological response of success (p =
1.000).
A total of 40 (26.8%) patients in the piperacillin/tazobactam
arm and 52 (36.1%) patients in the imipenem/cilastatin arm
experienced at least one adverse event. The most commonly
reported adverse events (defined as reported by at least 2% of
the ITT population) are summarized in Table 5. The incidence
and type of adverse events did not differ significantly between
the two groups. Twelve patients (8%) in the piperacillin/tazo-
bactam group and 12 (8%) in the imipenem/cilastatin group
experienced at least one adverse event considered related to
study drug by the investigator. One patient in the piperacillin/
tazobactam group withdrew from the study due to a drug-
related adverse event, compared with four patients in the imi-
penem/cilastatin group. Most adverse events occurred with a
maximum intensity of mild to moderate in both groups.
Three patients in the piperacillin/tazobactam group expe-
rienced a total of nine serious adverse events (SAEs), only one
of which (death due to septic shock) was considered possibly
related to study drug. A second patient experienced sepsis,
pneumonia, unstable blood pressure, urinary tract infection,
acute renal failure, heart failure and cardiac arrest, which
resulted in death. A third patient experienced aspiration
pneumonia, septic shock, acute renal failure, and multi-organ
dysfunction resulting in death. Five patients in the imipenem/
cilastatin group experienced a total of eight SAEs. Two in-
creases in aspartate aminotransferase (AST) were considered
probably related to study drug and were experienced by the
same patient. A second patient experienced pneumonia, reper-
foration of the duodenal ulcer, and sepsis. The other three
SAEs included a bile leak, intestinal obstruction and abdo-
minal pain.
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Table 3. Pathogen bacteriological response in the bacteriologically evaluable population*
Pathogen Piperacillin/tazobactam (n = 96) Imipenem/cilastatin (n = 99)
Escherichia coli
   Eradication 43/44 (97.7)1 40/42 (95.2)1
   Persistence 1/44 (2.3)1 2/42 (4.8)1
Klebsiella species
   Eradication 16/17 (94.1)1 15/16 (93.8)1
   Persistence 1/17 (5.9)1 1/16 (6.3)1
Enterobacter species
   Eradication 5/5 (100) 7/7 (100)
   Persistence 0 0
Pseudomonas aeruginosa
   Eradication 4/4 (100) 6/6 (100)
   Persistence 0 0
Bacteroides species
   Eradication 3/3 (100) 6/6 (100)
   Persistence 0 0
Enterococcus species
   Eradication 3/3 (100) 4/4 (100)
   Persistence 0 0
Staphylococcus aureus
   Eradication 3/3 (100) 3/3 (100)
   Persistence 0 0
*Most common pathogens are listed and one patient could have more than one pathogen; therefore, the number of pathogens listed does
not equal n.
Table 4. Clinical and bacteriological response rates
Outcome Piperacillin/tazobactam Imipenem/cilastatin p*
Bacteraemic bacteriologically evaluable patients
   Clinical response rate  n = 13 n = 18
      Cured/improved 13 (100%)1 17 (94.4%) 1.000
      Failure 0 1 (5.6%)
   Patient-level bacteriological response rate n = 13 n = 18
      Eradication documented/presumed 13 (100%)1 17 (94.4%) 1.000
      Persistence documented/presumed 0 1 (5.6%)
All treated patients with a baseline blood pathogen
   Clinical response rate  n = 17 n = 19
      Cured/improved 14 (82.4%)1 17 (89.5%) 0.650
      Failure/indeterminate 3 (17.6%) 12 (10.5%)
   Patient-level bacteriological response rate† n = 17 n = 19
      Eradication documented/presumed 14 (82.4%)1 17 (89.5%) 0.650
      Persistence documented/presumed 0 1 (5.3%)
      Indeterminate 3 (17.6%) 1 (5.3%)
      Superinfection 0 0
*Fisher’s exact test; †all treated patients with a baseline pathogen.
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Table 5. Summary of reported adverse events in the intent-to-treat population*
Adverse event
Piperacillin/tazobactam Imipenem/cilastatin p†
n (%) n (%)
All adverse events 149 (26.8)d 144(26.8)d
   Total patients with > 1 adverse event 40 (26.8) 52 (36.1) 0.114
   Alkaline phosphatase increased 1 (0.7) 3 (2.1) 0.364
   Cough increased 3 (2.0) 5 (3.5) 0.495
   Diarrhoea 7 (4.7) 3 (2.1) 0.336
   Fever 2 (1.3) 3 (2.1) 0.680
   Healing abnormal 0(26.8 4 (2.8) 0.057
   Hyperglycaemia 4 (2.7) 1 (0.7) 0.371
   Hypertension 2 (1.3) 7 (4.9) 0.099
   Hypoproteinaemia 3 (2.0) 6 (4.2) 0.329
   Infection‡ 7 (4.7) 1 (0.7) 0.067
   Laboratory test abnormal§ 2 (1.3) 5 (3.5) 0.276
   Nausea 2 (1.3) 3 (2.1) 0.680
   Pain 4 (2.7) 3 (2.1) 1.000
   Pleural effusion 0(26.8 3 (2.1) 0.117
   AST increased 2 (1.3) 3 (2.1) 0.680
   ALT increased 5 (3.4) 3 (2.1) 0.723
Adverse events related to study drug
   Total number of drug-related adverse events 16(216.8 19(26.8 0.640
   Total patients with > 1 adverse event 12 (8.1)1 12 (8.3) 0.900
   Allergic reaction 0(26.8 1 (0.7) 0.491
   Chest pain 0(26.8 1 (0.7) 0.491
   Fever 1 (0.7) 0(26.8 1.000
   Infection‡ 1 (0.7) 0(26.8 1.000
   Phlebitis 2 (1.3) 1 (0.7) 1.000
   Shock 1 (0.7) 0(26.8 1.000
   Infection 1 (0.7) 0(26.8 1.000
   Diarrhoea 5 (3.4) 1 (0.7) 0.214
   Duodenal ulcer 0(26.8 1 (0.7) 0.491
   Liver function tests abnormal 1 (0.7) 0(26.8 1.000
   Nausea 1 (0.7) 3 (2.1) 0.364
   Vomiting 1 (0.7) 1 (0.7) 1.000
   Abnormal platelets 0(26.8 1 (0.7) 0.491
   Healing abnormal 0(26.8 1 (0.7) 0.491
   Hypoproteinaemia 0(26.8 2 (1.4) 0.241
   AST increased 1 (0.7) 1 (0.7) 1.000
   ALT increased 1 (0.7) 1 (0.7) 1.000
   Insomnia 0(26.8 1 (0.7) 1.000
   Cough increased 0(26.8 1 (0.7) 0.491
   Dyspnoea 0(26.8 1 (0.7) 0.491
   Sweating 0(26.8 1 (0.7) 0.491
*Reported by at least 2% of intent-to-treat patients; †Fisher’s exact test; ‡patients who had infection at a non-intra-abdominal site during
the study (i.e. pneumonia), this term does not count superinfections (superinfection rate = 0 for both groups); §laboratory value out of
normal range. AST = aspartate aminotransferase; ALT = alanine aminotransferase.
Discussion
Intra-abdominal infections are usually polymicrobial, averag-
ing two to five bacterial species per infection site and involving
aerobic and anaerobic bacteria. Prompt initiation of empi-
ric, broad-spectrum antimicrobial therapy is essential to eradi-
cate pathogens to prevent further infection and accelerate re-
covery.4 Piperacillin, a penicillin derivative administered
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parenterally, has broad-spectrum antibacterial activity. The
piperacillin/tazobactam combination has in vitro activity
against resistant Gram-negative bacteria, β-lactamase produc-
ing staphylococci and anaerobic bacteria.5 It has been evalu-
ated in the treatment of intra-abdominal infections in several
clinical trials.3,6,8,10,11 In one trial, piperacillin/tazobactam
4 g/500 mg every 8 hours had higher clinical cure rates than
imipenem/cilastatin 500 mg/500 mg every 8 hours.10 Other
studies showed that piperacillin/tazobactam was equivalent
in efficacy and safety to imipenem/cilastatin.3,8,11
In the present study, we compared the efficacy and safety of
piperacillin/tazobactam to imipenem/cilastatin in the treat-
ment of intra-abdominal infections in an Asian population.
The results indicated that the efficacy and safety of piperacillin/
tazobactam was equivalent to those of imipenem/cilastatin.
Both drugs achieved excellent clinical success rates (97% each)
in the CE population and had equivalent success rates in the
bacteraemic subgroup. The clinical success rate with pipera-
cillin/tazobactam (97.3%) was comparable to that observed in
other studies comparing the treatment of intra-abdominal
infections with piperacillin/tazobactam and imipenem/
cilastatin.3,10–12
Both treatments were well tolerated, with comparable
numbers of adverse events. While diarrhoea and infection were
the most common adverse events reported in the piperacillin/
tazobactam group, hypertension and hypoproteinaemia were
the most common adverse events reported in the imipenem/
cilastatin group. These data are similar to adverse events
reported previously.3,11
The most common pathogens found in blood and in-
fection site cultures were E. coli and K. pneumoniae. These
are frequently encountered microorganisms in most intra-
abdominal infections. Our results showed that piperacillin/
tazobactam and imipenem/cilastatin are equivalent in eradi-
cating these bacterial species.
While the study results contribute additional data, specifi-
cally in an Asian population, the results of the present study
must be interpreted with certain limitations in mind. First,
this was an open-label study and results should be interpreted
accordingly. Secondly, although it is believed our findings are
applicable to all intra-abdominal infections, such generaliza-
tions should be made with caution as there was a predomi-
nance of appendicitis in the present study.
Conclusions
The efficacy of intravenous piperacillin/tazobactam 4 g/
500 mg every 8 hours is equivalent to that of intravenous
imipenem/cilastatin 500 mg/500 mg every 6 hours in the
treatment of intra-abdominal infections. Both treatments
achieved good clinical cure rates of 97% in the evaluable pop-
ulation. The frequency of adverse events was similar in the
two treatment groups. The most frequent cause of intra-
abdominal infection in this cohort was appendicitis. While the
clinical efficacy was similar in the two groups, the piperacillin/
tazobactam regimen had the advantage of fewer daily doses.
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